がんにおける二重特異性抗体のグローバル市場2023~2027:CD19/CD3、CD30/CD16A

【英語タイトル】Global Bispecific Antibodies for Cancer Market 2023-2027

Technavioが出版した調査資料(IRTNTR72677-23)・商品コード:IRTNTR72677-23
・発行会社(調査会社):Technavio
・発行日:2023年2月22日
・ページ数:約120
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:北米、ヨーロッパ、アジア太平洋、その他地域
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥370,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥592,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Technavio社の本調査レポートによると、世界のがんにおける二重特異性抗体市場規模が2022年から2027年の間に400.72百万ドルに達すると予測されており、予測期間中に年平均8.82%成長すると見込まれます。本書ではがんにおける二重特異性抗体の世界市場について調査・分析し、エグゼクティブサマリー、市場状況、市場規模予測、過去の市場規模、ファイブフォース分析、種類別(CD19/CD3、CD30/CD16A)分析、流通チャネル別(病院、小売薬局、オンライン)分析、顧客状況、地域別状況(北米、アジア太平洋、ヨーロッパ、中東・アフリカ、南米、アメリカ、アイルランド、中国、ハンガリー、インド)分析、成長要因・課題・動向、企業状況、企業分析などの内容を掲載しています。なお、本書には、ABL Bio Inc., AFFIMED N.V., Akeso Inc., Amgen Inc., Aptevo Therapeutics Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly and Co., EPIMAB BIOTHERAPEUTICS INC., F STAR THERAPEUTICS INC.などの企業情報が含まれています。
・エグゼクティブサマリー
・市場状況
・市場規模予測
・過去の市場規模
・ファイブフォース分析

・世界のがんにおける二重特異性抗体市場規模:サービス別
- CD19/CD3の市場規模
- CD30/CD16Aの市場規模

・世界のがんにおける二重特異性抗体市場規模:流通チャネル別
- 病院チャネルの市場規模
- 小売薬局チャネルの市場規模
- オンラインチャネルの市場規模

・顧客状況
・地域別状況
- 北米のがんにおける二重特異性抗体市場規模
- ヨーロッパのがんにおける二重特異性抗体市場規模
- アジア太平洋のがんにおける二重特異性抗体市場規模
- その他地域のがんにおける二重特異性抗体市場規模
- アイルランドのがんにおける二重特異性抗体市場規模
- 中国のがんにおける二重特異性抗体市場規模
- ハンガリーのがんにおける二重特異性抗体市場規模
- インドのがんにおける二重特異性抗体市場規模

・成長要因・課題・動向
・企業状況
・企業分析

Technavio社は、利益、価格、競争、プロモーションなどの主要なパラメーターを分析することにより、また複数のソースからのデータを調査、統合、および合計することにより、がんにおける二重特異性抗体市場の詳細な全体像を提示します。主要産業のインフルエンサーを特定することにより、さまざまな市場の側面を提示します。提示されたデータは包括的​​で信頼性が高く、一次および二次の広範な調査の結果です。Technavio社の市場調査レポートは、正確ながんにおける二重特異性抗体市場の成長を予測するための定性的および定量的調査を使用し、完全な競争状況と詳細なベンダー選択方法と分析を提供します。

がんにおける二重特異性抗体の世界市場 2023-2027

Technavio社は、がんにおける二重特異性抗体市場をモニターしており、2022年から2027年にかけて400.72百万ドルの成長が予測され、予測期間中のCAGRは8.82%で加速すると予測しています。当レポートでは、がんにおける二重特異性抗体市場について、市場規模や予測、動向、成長促進要因、課題などの全体的な分析に加え、約25のベンダーを網羅したベンダー分析も掲載しています。

当レポートでは、現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。がんの有病率の増加、モノクローナル抗体に対する二重特異性抗体の優位性、強力なパイプラインなどが市場を牽引しています。

Technavio社のがんにおける二重特異性抗体市場は以下のように分類されます:

・タイプ別:
– CD19/CD3
– CD30/CD16A

・販売チャネル別:
– 病院
– 小売薬局
– オンライン

・地域別:
– 北米
– ヨーロッパ
– アジア
– その他の地域(ROW)

本調査では、今後数年間における癌用二特異性抗体市場の成長を促進する主な要因の一つとして、新たな二特異性抗体生成プラットフォームを挙げています。また、戦略的提携の増加や、中国における強力な研究開発が、市場の大きな需要につながるとしています。

Technavio社は、複数の情報源からのデータを調査、合成、要約し、主要パラメータの分析によって、市場の詳細な姿を提示します。

当レポートでは、がんにおける二重特異性抗体市場について以下の分野をカバーしています:
– がんにおける二重特異性抗体市場のサイジング
– がんにおける二重特異性抗体市場予測
– がんにおける二重特異性抗体市場の産業分析

Technavio社の確実なベンダー分析は、クライアントが市場でのポジションを向上できるように設計されており、これに沿って本レポートには、ABL Bio Inc., AFFIMED N.V., Akeso Inc., Amgen Inc., Aptevo Therapeutics Inc., Astellas Pharma Inc., Chugai Pharmaceutical Co. Ltd., Eli Lilly and Co., EPIMAB BIOTHERAPEUTICS INC., F STAR THERAPEUTICS INC., F. Hoffmann La Roche Ltd., Glenmark Pharmaceuticals Ltd., Johnson and Johnson, Mereo BioPharma Group Plc, Merus N.V., Pfizer Inc., Regeneron Pharmaceuticals Inc., TG Therapeutics Inc., Xencor Inc., and Y mAbs Therapeutics Incなどの企業情報が含まれています。また、がんにおける二重特異性抗体の市場分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。本レポートでは、主要ベンダーの分析に加え、包括的な市場およびベンダーの状況を掲載しています。

Technavioは、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、要約する方法で、市場の詳細な姿を提示します。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示します。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。Technavioの市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market by Geography
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Type
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global bispecific antibodies for cancer market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on Global bispecific antibodies for cancer market 2017 – 2021 ($ million)
o 4.2 Type Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Type Segment 2017 – 2021 ($ million)
o 4.3 Distribution channel Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Distribution channel Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Type
o 6.1 Market segments
o Exhibit 30: Chart on Type – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Type – Market share 2022-2027 (%)
o 6.2 Comparison by Type
o Exhibit 32: Chart on Comparison by Type
o Exhibit 33: Data Table on Comparison by Type
o 6.3 CD19 or CD3 – Market size and forecast 2022-2027
o Exhibit 34: Chart on CD19 or CD3 – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on CD19 or CD3 – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on CD19 or CD3 – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on CD19 or CD3 – Year-over-year growth 2022-2027 (%)
o 6.4 CD30 or CD16A – Market size and forecast 2022-2027
o Exhibit 38: Chart on CD30 or CD16A – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on CD30 or CD16A – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on CD30 or CD16A – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on CD30 or CD16A – Year-over-year growth 2022-2027 (%)
o 6.5 Market opportunity by Type
o Exhibit 42: Market opportunity by Type ($ million)
o Exhibit 43: Data Table on Market opportunity by Type ($ million)
• 7 Market Segmentation by Distribution Channel
o 7.1 Market segments
o Exhibit 44: Chart on Distribution Channel – Market share 2022-2027 (%)
o Exhibit 45: Data Table on Distribution Channel – Market share 2022-2027 (%)
o 7.2 Comparison by Distribution Channel
o Exhibit 46: Chart on Comparison by Distribution Channel
o Exhibit 47: Data Table on Comparison by Distribution Channel
o 7.3 Hospitals – Market size and forecast 2022-2027
o Exhibit 48: Chart on Hospitals – Market size and forecast 2022-2027 ($ million)
o Exhibit 49: Data Table on Hospitals – Market size and forecast 2022-2027 ($ million)
o Exhibit 50: Chart on Hospitals – Year-over-year growth 2022-2027 (%)
o Exhibit 51: Data Table on Hospitals – Year-over-year growth 2022-2027 (%)
o 7.4 Retail pharmacies – Market size and forecast 2022-2027
o Exhibit 52: Chart on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Data Table on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 54: Chart on Retail pharmacies – Year-over-year growth 2022-2027 (%)
o Exhibit 55: Data Table on Retail pharmacies – Year-over-year growth 2022-2027 (%)
o 7.5 Online – Market size and forecast 2022-2027
o Exhibit 56: Chart on Online – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Data Table on Online – Market size and forecast 2022-2027 ($ million)
o Exhibit 58: Chart on Online – Year-over-year growth 2022-2027 (%)
o Exhibit 59: Data Table on Online – Year-over-year growth 2022-2027 (%)
o 7.6 Market opportunity by Distribution Channel
o Exhibit 60: Market opportunity by Distribution Channel ($ million)
o Exhibit 61: Data Table on Market opportunity by Distribution Channel ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 63: Chart on Market share by geography 2022-2027 (%)
o Exhibit 64: Data Table on Market share by geography 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 65: Chart on Geographic comparison
o Exhibit 66: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 67: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 68: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 69: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 70: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 71: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 72: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 73: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 74: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 75: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 76: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 77: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 78: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 79: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 80: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 81: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 82: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 83: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 84: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 85: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 86: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 Ireland – Market size and forecast 2022-2027
o Exhibit 87: Chart on Ireland – Market size and forecast 2022-2027 ($ million)
o Exhibit 88: Data Table on Ireland – Market size and forecast 2022-2027 ($ million)
o Exhibit 89: Chart on Ireland – Year-over-year growth 2022-2027 (%)
o Exhibit 90: Data Table on Ireland – Year-over-year growth 2022-2027 (%)
o 9.9 China – Market size and forecast 2022-2027
o Exhibit 91: Chart on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 92: Data Table on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 93: Chart on China – Year-over-year growth 2022-2027 (%)
o Exhibit 94: Data Table on China – Year-over-year growth 2022-2027 (%)
o 9.10 Hungary – Market size and forecast 2022-2027
o Exhibit 95: Chart on Hungary – Market size and forecast 2022-2027 ($ million)
o Exhibit 96: Data Table on Hungary – Market size and forecast 2022-2027 ($ million)
o Exhibit 97: Chart on Hungary – Year-over-year growth 2022-2027 (%)
o Exhibit 98: Data Table on Hungary – Year-over-year growth 2022-2027 (%)
o 9.11 India – Market size and forecast 2022-2027
o Exhibit 99: Chart on India – Market size and forecast 2022-2027 ($ million)
o Exhibit 100: Data Table on India – Market size and forecast 2022-2027 ($ million)
o Exhibit 101: Chart on India – Year-over-year growth 2022-2027 (%)
o Exhibit 102: Data Table on India – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity by geography
o Exhibit 103: Market opportunity by geography ($ million)
o Exhibit 104: Data Tables on Market opportunity by geography ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 105: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 107: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 108: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 109: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 110: Matrix on vendor position and classification
o 12.3 ABL Bio Inc.
o Exhibit 111: ABL Bio Inc. – Overview
o Exhibit 112: ABL Bio Inc. – Product / Service
o Exhibit 113: ABL Bio Inc. – Key offerings
o 12.4 AFFIMED N.V.
o Exhibit 114: AFFIMED N.V. – Overview
o Exhibit 115: AFFIMED N.V. – Product / Service
o Exhibit 116: AFFIMED N.V. – Key offerings
o 12.5 Akeso Inc.
o Exhibit 117: Akeso Inc. – Overview
o Exhibit 118: Akeso Inc. – Product / Service
o Exhibit 119: Akeso Inc. – Key offerings
o 12.6 Amgen Inc.
o Exhibit 120: Amgen Inc. – Overview
o Exhibit 121: Amgen Inc. – Product / Service
o Exhibit 122: Amgen Inc. – Key offerings
o 12.7 Aptevo Therapeutics Inc.
o Exhibit 123: Aptevo Therapeutics Inc. – Overview
o Exhibit 124: Aptevo Therapeutics Inc. – Product / Service
o Exhibit 125: Aptevo Therapeutics Inc. – Key offerings
o 12.8 Astellas Pharma Inc.
o Exhibit 126: Astellas Pharma Inc. – Overview
o Exhibit 127: Astellas Pharma Inc. – Product / Service
o Exhibit 128: Astellas Pharma Inc. – Key offerings
o 12.9 Chugai Pharmaceutical Co. Ltd.
o Exhibit 129: Chugai Pharmaceutical Co. Ltd. – Overview
o Exhibit 130: Chugai Pharmaceutical Co. Ltd. – Product / Service
o Exhibit 131: Chugai Pharmaceutical Co. Ltd. – Key offerings
o 12.10 Eli Lilly and Co.
o Exhibit 132: Eli Lilly and Co. – Overview
o Exhibit 133: Eli Lilly and Co. – Product / Service
o Exhibit 134: Eli Lilly and Co. – Key offerings
o 12.11 EPIMAB BIOTHERAPEUTICS INC.
o Exhibit 135: EPIMAB BIOTHERAPEUTICS INC. – Overview
o Exhibit 136: EPIMAB BIOTHERAPEUTICS INC. – Product / Service
o Exhibit 137: EPIMAB BIOTHERAPEUTICS INC. – Key offerings
o 12.12 F STAR THERAPEUTICS INC.
o Exhibit 138: F STAR THERAPEUTICS INC. – Overview
o Exhibit 139: F STAR THERAPEUTICS INC. – Product / Service
o Exhibit 140: F STAR THERAPEUTICS INC. – Key offerings
o 12.13 F. Hoffmann La Roche Ltd.
o Exhibit 141: F. Hoffmann La Roche Ltd. – Overview
o Exhibit 142: F. Hoffmann La Roche Ltd. – Business segments
o Exhibit 143: F. Hoffmann La Roche Ltd. – Key news
o Exhibit 144: F. Hoffmann La Roche Ltd. – Key offerings
o Exhibit 145: F. Hoffmann La Roche Ltd. – Segment focus
o 12.14 Glenmark Pharmaceuticals Ltd.
o Exhibit 146: Glenmark Pharmaceuticals Ltd. – Overview
o Exhibit 147: Glenmark Pharmaceuticals Ltd. – Product / Service
o Exhibit 148: Glenmark Pharmaceuticals Ltd. – Key offerings
o 12.15 Johnson and Johnson
o Exhibit 149: Johnson and Johnson – Overview
o Exhibit 150: Johnson and Johnson – Business segments
o Exhibit 151: Johnson and Johnson – Key news
o Exhibit 152: Johnson and Johnson – Key offerings
o Exhibit 153: Johnson and Johnson – Segment focus
o 12.16 Mereo BioPharma Group Plc
o Exhibit 154: Mereo BioPharma Group Plc – Overview
o Exhibit 155: Mereo BioPharma Group Plc – Product / Service
o Exhibit 156: Mereo BioPharma Group Plc – Key offerings
o 12.17 Merus N.V.
o Exhibit 157: Merus N.V. – Overview
o Exhibit 158: Merus N.V. – Product / Service
o Exhibit 159: Merus N.V. – Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 160: Inclusions checklist
o Exhibit 161: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 162: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 163: Research methodology
o Exhibit 164: Validation techniques employed for market sizing
o Exhibit 165: Information sources
o 13.5 List of abbreviations
o Exhibit 166: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market by Geography
Exhibits5: Executive Summary – Chart on Market Segmentation by Type
Exhibits6: Executive Summary – Chart on Market Segmentation by Distribution Channel
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on Global bispecific antibodies for cancer market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Type Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Distribution channel Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Type – Market share 2022-2027 (%)
Exhibits31: Data Table on Type – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Type
Exhibits33: Data Table on Comparison by Type
Exhibits34: Chart on CD19 or CD3 – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on CD19 or CD3 – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on CD19 or CD3 – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on CD19 or CD3 – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on CD30 or CD16A – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on CD30 or CD16A – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on CD30 or CD16A – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on CD30 or CD16A – Year-over-year growth 2022-2027 (%)
Exhibits42: Market opportunity by Type ($ million)
Exhibits43: Data Table on Market opportunity by Type ($ million)
Exhibits44: Chart on Distribution Channel – Market share 2022-2027 (%)
Exhibits45: Data Table on Distribution Channel – Market share 2022-2027 (%)
Exhibits46: Chart on Comparison by Distribution Channel
Exhibits47: Data Table on Comparison by Distribution Channel
Exhibits48: Chart on Hospitals – Market size and forecast 2022-2027 ($ million)
Exhibits49: Data Table on Hospitals – Market size and forecast 2022-2027 ($ million)
Exhibits50: Chart on Hospitals – Year-over-year growth 2022-2027 (%)
Exhibits51: Data Table on Hospitals – Year-over-year growth 2022-2027 (%)
Exhibits52: Chart on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits53: Data Table on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits54: Chart on Retail pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits55: Data Table on Retail pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits56: Chart on Online – Market size and forecast 2022-2027 ($ million)
Exhibits57: Data Table on Online – Market size and forecast 2022-2027 ($ million)
Exhibits58: Chart on Online – Year-over-year growth 2022-2027 (%)
Exhibits59: Data Table on Online – Year-over-year growth 2022-2027 (%)
Exhibits60: Market opportunity by Distribution Channel ($ million)
Exhibits61: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits63: Chart on Market share by geography 2022-2027 (%)
Exhibits64: Data Table on Market share by geography 2022-2027 (%)
Exhibits65: Chart on Geographic comparison
Exhibits66: Data Table on Geographic comparison
Exhibits67: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits68: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits69: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits70: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits71: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits72: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits73: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits74: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits75: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits76: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits77: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits78: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits79: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits80: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits81: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits82: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits83: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits84: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits85: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits86: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits87: Chart on Ireland – Market size and forecast 2022-2027 ($ million)
Exhibits88: Data Table on Ireland – Market size and forecast 2022-2027 ($ million)
Exhibits89: Chart on Ireland – Year-over-year growth 2022-2027 (%)
Exhibits90: Data Table on Ireland – Year-over-year growth 2022-2027 (%)
Exhibits91: Chart on China – Market size and forecast 2022-2027 ($ million)
Exhibits92: Data Table on China – Market size and forecast 2022-2027 ($ million)
Exhibits93: Chart on China – Year-over-year growth 2022-2027 (%)
Exhibits94: Data Table on China – Year-over-year growth 2022-2027 (%)
Exhibits95: Chart on Hungary – Market size and forecast 2022-2027 ($ million)
Exhibits96: Data Table on Hungary – Market size and forecast 2022-2027 ($ million)
Exhibits97: Chart on Hungary – Year-over-year growth 2022-2027 (%)
Exhibits98: Data Table on Hungary – Year-over-year growth 2022-2027 (%)
Exhibits99: Chart on India – Market size and forecast 2022-2027 ($ million)
Exhibits100: Data Table on India – Market size and forecast 2022-2027 ($ million)
Exhibits101: Chart on India – Year-over-year growth 2022-2027 (%)
Exhibits102: Data Table on India – Year-over-year growth 2022-2027 (%)
Exhibits103: Market opportunity by geography ($ million)
Exhibits104: Data Tables on Market opportunity by geography ($ million)
Exhibits105: Impact of drivers and challenges in 2022 and 2027
Exhibits106: Overview on Criticality of inputs and Factors of differentiation
Exhibits107: Overview on factors of disruption
Exhibits108: Impact of key risks on business
Exhibits109: Vendors covered
Exhibits110: Matrix on vendor position and classification
Exhibits111: ABL Bio Inc. – Overview
Exhibits112: ABL Bio Inc. – Product / Service
Exhibits113: ABL Bio Inc. – Key offerings
Exhibits114: AFFIMED N.V. – Overview
Exhibits115: AFFIMED N.V. – Product / Service
Exhibits116: AFFIMED N.V. – Key offerings
Exhibits117: Akeso Inc. – Overview
Exhibits118: Akeso Inc. – Product / Service
Exhibits119: Akeso Inc. – Key offerings
Exhibits120: Amgen Inc. – Overview
Exhibits121: Amgen Inc. – Product / Service
Exhibits122: Amgen Inc. – Key offerings
Exhibits123: Aptevo Therapeutics Inc. – Overview
Exhibits124: Aptevo Therapeutics Inc. – Product / Service
Exhibits125: Aptevo Therapeutics Inc. – Key offerings
Exhibits126: Astellas Pharma Inc. – Overview
Exhibits127: Astellas Pharma Inc. – Product / Service
Exhibits128: Astellas Pharma Inc. – Key offerings
Exhibits129: Chugai Pharmaceutical Co. Ltd. – Overview
Exhibits130: Chugai Pharmaceutical Co. Ltd. – Product / Service
Exhibits131: Chugai Pharmaceutical Co. Ltd. – Key offerings
Exhibits132: Eli Lilly and Co. – Overview
Exhibits133: Eli Lilly and Co. – Product / Service
Exhibits134: Eli Lilly and Co. – Key offerings
Exhibits135: EPIMAB BIOTHERAPEUTICS INC. – Overview
Exhibits136: EPIMAB BIOTHERAPEUTICS INC. – Product / Service
Exhibits137: EPIMAB BIOTHERAPEUTICS INC. – Key offerings
Exhibits138: F STAR THERAPEUTICS INC. – Overview
Exhibits139: F STAR THERAPEUTICS INC. – Product / Service
Exhibits140: F STAR THERAPEUTICS INC. – Key offerings
Exhibits141: F. Hoffmann La Roche Ltd. – Overview
Exhibits142: F. Hoffmann La Roche Ltd. – Business segments
Exhibits143: F. Hoffmann La Roche Ltd. – Key news
Exhibits144: F. Hoffmann La Roche Ltd. – Key offerings
Exhibits145: F. Hoffmann La Roche Ltd. – Segment focus
Exhibits146: Glenmark Pharmaceuticals Ltd. – Overview
Exhibits147: Glenmark Pharmaceuticals Ltd. – Product / Service
Exhibits148: Glenmark Pharmaceuticals Ltd. – Key offerings
Exhibits149: Johnson and Johnson – Overview
Exhibits150: Johnson and Johnson – Business segments
Exhibits151: Johnson and Johnson – Key news
Exhibits152: Johnson and Johnson – Key offerings
Exhibits153: Johnson and Johnson – Segment focus
Exhibits154: Mereo BioPharma Group Plc – Overview
Exhibits155: Mereo BioPharma Group Plc – Product / Service
Exhibits156: Mereo BioPharma Group Plc – Key offerings
Exhibits157: Merus N.V. – Overview
Exhibits158: Merus N.V. – Product / Service
Exhibits159: Merus N.V. – Key offerings
Exhibits160: Inclusions checklist
Exhibits161: Exclusions checklist
Exhibits162: Currency conversion rates for US$
Exhibits163: Research methodology
Exhibits164: Validation techniques employed for market sizing
Exhibits165: Information sources
Exhibits166: List of abbreviations



★調査レポート[がんにおける二重特異性抗体のグローバル市場2023~2027:CD19/CD3、CD30/CD16A] (コード:IRTNTR72677-23)販売に関する免責事項を必ずご確認ください。
★調査レポート[がんにおける二重特異性抗体のグローバル市場2023~2027:CD19/CD3、CD30/CD16A]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆